Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2021-06-15 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter responding to comments from the SEC staff regarding a Draft Registration Statement on Form S-1 submitted by JATT Acquisition Corp. It addresses specific SEC comments on risk factors, exclusive forum provisions, related party transactions, and signature blocks. The document is not the registration statement itself but a correspondence related to the SEC review process of the Form S-1 filing. It is a regulatory communication rather than a financial report or announcement of a meeting or vote. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-06-15 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of securities by JATT Acquisition Corp. The text includes detailed information about the offering, the securities being registered, underwriting details, and other disclosures typical of an IPO registration statement. This type of filing is related to capital raising and financing activities. According to the filing definitions, updates on company fundraising or financing activities fall under the category 'Capital/Financing Update' (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering, which aligns with CAP.
2021-06-15 English
Regulatory Filings 2021
Regulatory Filings
2021-05-05 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission on Form S-1. It includes detailed information about the company's securities offering, underwriting, business strategy, risk factors, and financial data summary. Form S-1 is used for initial public offerings (IPOs) and registration of securities under the Securities Act of 1933. This is a capital markets filing related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, supporting a high confidence score.
2021-04-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.